KalVista Pharmaceuticals Files 8-K on Agreements and Equity Sales
Ticker: KALV · Form: 8-K · Filed: Sep 29, 2025 · CIK: 1348911
| Field | Detail |
|---|---|
| Company | Kalvista Pharmaceuticals, Inc. (KALV) |
| Form Type | 8-K |
| Filed Date | Sep 29, 2025 |
| Risk Level | medium |
| Pages | 8 |
| Reading Time | 10 min |
| Key Dollar Amounts | $0.001, $143.75 million, $18.75 million, $139.0 m, $25.0 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, equity-sale, corporate-filing
TL;DR
KalVista Pharma filed an 8-K detailing new agreements and equity sales, plus past name changes.
AI Summary
On September 24, 2025, KalVista Pharmaceuticals, Inc. entered into a material definitive agreement, likely related to its financial obligations. The company also reported on unregistered sales of equity securities and other events. This filing follows a period of corporate changes, including previous name changes from Carbylan Therapeutics, Inc. and Carbylan Biosurgery, Inc.
Why It Matters
This 8-K filing indicates significant corporate activity, including new agreements and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.
Key Players & Entities
- KalVista Pharmaceuticals, Inc. (company) — Registrant
- Carbylan Therapeutics, Inc. (company) — Former company name
- Carbylan Biosurgery, Inc (company) — Former company name
- September 24, 2025 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by KalVista Pharmaceuticals?
The filing indicates the entry into a material definitive agreement and the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, but the specific details of the agreement are not provided in this excerpt.
What information is provided regarding unregistered sales of equity securities?
The filing lists 'Unregistered Sales of Equity Securities' as an item information, suggesting such sales have occurred, but specific details like the amount or price are not in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on September 24, 2025.
What were KalVista Pharmaceuticals' previous company names?
KalVista Pharmaceuticals, Inc. was formerly known as Carbylan Therapeutics, Inc. and Carbylan Biosurgery, Inc.
What is the Standard Industrial Classification (SIC) code for KalVista Pharmaceuticals?
The Standard Industrial Classification code for KalVista Pharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 2,396 words · 10 min read · ~8 pages · Grade level 12.7 · Accepted 2025-09-29 16:27:33
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share KALV The Nasdaq
- $143.75 million — pleted its previously announced sale of $143.75 million in aggregate principal amount of its 3.
- $18.75 million — option to purchase up to an additional $18.75 million in aggregate principal amount of Notes,
- $139.0 m — eds from the offering are approximately $139.0 million, after deducting the Initial Purc
- $25.0 m — tstanding principal amount in excess of $25.0 million, which indebtedness is not discha
- $1,000 — e is 59.4919 shares of Common Stock per $1,000 principal amount of the Notes, which is
- $16.81 — itial conversion price of approximately $16.81 per share of Common Stock subject to ad
Filing Documents
- d83242d8k.htm (8-K) — 46KB
- d83242dex41.htm (EX-4.1) — 556KB
- d83242dex991.htm (EX-99.1) — 9KB
- d83242dex992.htm (EX-99.2) — 10KB
- g83242g0929022758781.jpg (GRAPHIC) — 2KB
- g83242g0929022759062.jpg (GRAPHIC) — 3KB
- g83242g0929022759250.jpg (GRAPHIC) — 2KB
- g83242g0929022759437.jpg (GRAPHIC) — 3KB
- g83242g0929022759593.jpg (GRAPHIC) — 3KB
- g83242g0929022759750.jpg (GRAPHIC) — 3KB
- 0001193125-25-223262.txt ( ) — 884KB
- kalv-20250924.xsd (EX-101.SCH) — 3KB
- kalv-20250924_lab.xml (EX-101.LAB) — 17KB
- kalv-20250924_pre.xml (EX-101.PRE) — 11KB
- d83242d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KALVISTA PHARMACEUTICALS, INC. Date: September 29, 2025 By: /s/ Brian Piekos Brian Piekos Chief Financial Officer (Principal Financial and Accounting Officer)